Abstract
Intravascular iodinated contrast agents are required for a large proportion of computed tomography (CT) studies. Contrast media are indispensable to more clearly differentiate anatomic structures and to detect and characterize abnormalities. Depending on the indication up to 200 ml of these agents are injected during CT. Despite these large amounts adverse effects are rare and have further decreased with the introduction of non-ionic substances. However, it took 10 to 20 years until these non-ionic agents replaced the older ionic agents in clinical practice. In recent years no new substance has been brought to the market. The introduction of rapid scanning using multislice CT technology, however, has led to the development of more sophisticated contrast injection techniques. Current research focuses on optimizing contrast application techniques and on further evaluating the safety profiles of the various substances. The amount of contrast enhancement obtained in individual patients for instance depends on the contrast agent characteristics, such as iodine concentration, and the parameters of the contrast injection protocol, such as iodine flux and iodine dose. Meanwhile, contrast agent characteristics such as osmolality and viscosity play a role in the safety profile of an agent. This paper provides a current overview of CT contrast media, CT contrast dynamics, and CT contrast applications with a special focus on oncological imaging.
Keywords: oncological imaging, computed tomography, contrast medium, Iodinated contrast agents
Anti-Cancer Agents in Medicinal Chemistry
Title: Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Volume: 7 Issue: 3
Author(s): Annemarieke Rutten and Mathias Prokop
Affiliation:
Keywords: oncological imaging, computed tomography, contrast medium, Iodinated contrast agents
Abstract: Intravascular iodinated contrast agents are required for a large proportion of computed tomography (CT) studies. Contrast media are indispensable to more clearly differentiate anatomic structures and to detect and characterize abnormalities. Depending on the indication up to 200 ml of these agents are injected during CT. Despite these large amounts adverse effects are rare and have further decreased with the introduction of non-ionic substances. However, it took 10 to 20 years until these non-ionic agents replaced the older ionic agents in clinical practice. In recent years no new substance has been brought to the market. The introduction of rapid scanning using multislice CT technology, however, has led to the development of more sophisticated contrast injection techniques. Current research focuses on optimizing contrast application techniques and on further evaluating the safety profiles of the various substances. The amount of contrast enhancement obtained in individual patients for instance depends on the contrast agent characteristics, such as iodine concentration, and the parameters of the contrast injection protocol, such as iodine flux and iodine dose. Meanwhile, contrast agent characteristics such as osmolality and viscosity play a role in the safety profile of an agent. This paper provides a current overview of CT contrast media, CT contrast dynamics, and CT contrast applications with a special focus on oncological imaging.
Export Options
About this article
Cite this article as:
Rutten Annemarieke and Prokop Mathias, Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618162
DOI https://dx.doi.org/10.2174/187152007780618162 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Peroxisome Proliferator-Activated Receptor-γ: Master Regulator of Adipogenesis and Obesity
Current Stem Cell Research & Therapy A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation
Current Pharmaceutical Design Editorial: The Interplay between TSH and Lipids. What Should Clinicians Know?
Current Vascular Pharmacology A Hemagglutinin from Northeast Red Beans with Immunomodulatory Activity and Anti-proliferative and Apoptosis-inducing Activities Toward Tumor Cells
Protein & Peptide Letters Physical Activity and Hypertension: Evidence of Cross-Sectional Studies,Cohort Studies and Meta-Analysis
Current Hypertension Reviews Editorial (Thematic Issue: Cardio-Metabolic Complications: Current Perspective and Future Developments)
Current Pharmaceutical Design Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Drug-Eluting Stents: Present and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design Risk Scores for Patients with Chest Pain: Evaluation in the Emergency Department
Current Cardiology Reviews Congestive Heart Failure and Thyroid Dysfunction: The Role of the Low T3 Syndrome and Therapeutic Aspects
Endocrine, Metabolic & Immune Disorders - Drug Targets Specific Therapy Based on the Genotype and Cellular Mechanism in Inherited Cardiac Arrhythmias. Long QT Syndrome and Brugada Syndrome
Current Pharmaceutical Design Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Meet Our Regional Editor
Current Vascular Pharmacology